Molecular Imaging in Neuroendocrine Differentiation of Prostate Cancer
Authors:
- Sharjeel UsmaniSharjeel Usmani
- Najeeb AhmedNANajeeb Ahmed
- Fahad MarafiFMFahad Marafi
- Rashid RasheedRRRashid Rasheed
- Henney G. AmangunoHAHenney G. Amanguno
- Fareeda al KandariFKFareeda al Kandari
- 1 May 2017
- journal article
- case report
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (5) , 410-413
Abstract
We report on a 62-year-old man with metastatic prostate cancer (cT3b N1) diagnosed in 2011, treated with total androgen blockage with flutamide and goserelin acetate (Zoladex). He presented with left suprascapular swelling and low-back pain after being asymptomatic for 5 years. His prostate-specific antigen was 0.049 ng/mL. 18F-NaF PET-CT and 68Ga-PSMA scan were negative, whereas 68Ga-DOTA NOC scan done after 10 days showed multiple somatostatin-avid hepatic and lymph node metastasis.Keywords
This publication has 7 references indexed in Scilit:
- Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesJournal of the National Comprehensive Cancer Network, 2014
- Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATEEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Chromogranin A Expression in Patients With Hormone Naïve Prostate Cancer Predicts the Development of Hormone Refractory DiseaseJournal of Urology, 2007
- 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5European Journal of Nuclear Medicine and Molecular Imaging, 2004
- Neuroendocrine Differentiation in Hormone Refractory Prostate Cancer Following Androgen Deprivation TherapyEuropean Urology, 2004
- Neuroendocrine differentiation in human prostatic carcinomaHuman Pathology, 1992